Background: Preparations of commercially available clotting factor VIII are complex protein mixtures. Most of them contain either von Willebrand factor or human serum albumin as stabilizers. The aim of the study was to quantify further proteins in twelve concentrates either of recombinant origin or derived from human plasma. Methods: Proteins were separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Some proteins were quantified by ELISA. Results: Recombinant clotting factor preparations showed fewer protein spots in the 2D-PAGE, than plasma-derived preparations. Proteins identified in some of the plasma-derived concentrates included up to 90 ng/IU of the anaphylatoxin C3a, up to 40 ng/IU of the platelet a-granule protein thrombospondin-1, up to 0.85 ng/IU of the platelet agranule protein platelet factor 4, 3.5 ng/IU myeloperoxidase secreted by leukocytes and up to 0.05 ng/IU of the leukocyte-secreted protein a-defensin. The protein content differed between concentrates from different manufacturers. Conclusion: The origin of the plasma used to prepare the factor concentrates might influence the protein impurities in these products. It is unknown whether the impurities observed have long-term consequences for chronic inflammatory conditions. 
Summary
Background: Preparations of commercially available clotting factor VIII are complex protein mixtures. Most of them contain either von Willebrand factor or human serum albumin as stabilizers. The aim of the study was to quantify further proteins in twelve concentrates either of recombinant origin or derived from human plasma. Methods: Proteins were separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). Some proteins were quantified by ELISA. Results: Recombinant clotting factor preparations showed fewer protein spots in the 2D-PAGE, than plasma-derived preparations. Proteins identified in some of the plasma-derived concentrates included up to 90 ng/IU of the anaphylatoxin C3a, up to 40 ng/IU of the platelet a-granule protein thrombospondin-1, up to 0.85 ng/IU of the platelet agranule protein platelet factor 4, 3.5 ng/IU myeloperoxidase secreted by leukocytes and up to 0.05 ng/IU of the leukocyte-secreted protein a-defensin. The protein content differed between concentrates from different manufacturers. Conclusion: The origin of the plasma used to prepare the factor concentrates might influence the protein impurities in these products. It is unknown whether the impurities observed have long-term consequences for chronic inflammatory conditions.
Schlüsselwörter
Gerinnungsfaktor VIII · Hämophilie · Leukozyten · Thrombozyten · Von-Willebrand-Faktor [1] , and since then the standard treatment for patients with severe hemophilia A has been clotting factor replacement therapy with FVIII concentrates.
The products used today for replacement therapy are either recombinant FVIII concentrates or concentrates derived from human plasma. Plasma for fractionation is either derived from source plasma, obtained by automated plasmapheresis, or from recovered plasma, being prepared from whole blood, mainly as a by-product of red cell production.
Hemophilia patients require treatment for their whole life, and the lifetime requirement of factor concentrates is high. In a recent study by Manco-Johnson et al. [2] , the number of FVIII units administered per patient and year was approximately 6,000 IU/kg in the prophylaxis group and 2,500 IU/kg in the episodic-therapy group. Although high safety standards with regard to the potential transmission of infections have been achieved for all coagulation factor concentrates used today, in view of the huge lifetime requirement of FVIII in hemophilia A patients even small impurities may have a major health impact in such patients. Most clotting factor concentrates contain von Willebrand factor (vWF) or human serum albumin as stabilizer.
The aim of this study was to identify and quantify additional proteins, namely the neutrophil activation marker, adefensins (human neutrophil peptide (HNP) 1-3), myeloperoxidase, the platelet activation markers platelet factor 4 (PF-4) and thrombospondin-1 (TSP-1) and anaphylatoxin C3a, a product of complement activation, in twelve concentrates isolated from human plasma (eight concentrates) or made by genetically engineered cells (four concentrates). concentrates showed several protein bands in that area ( fig.  1c ). As expected, prominent bands were seen for some of the plasma-derived concentrates in the molecular ranges described for human albumin and fibrinogen. All plasma-derived concentrates showed bands at the position of vWf. To achieve better separation of proteins and polypeptides, the concentrates were analyzed using 2D-PAGE with isoelectric focussing in the first dimension using nonlinear IPG strips concentrates ( fig. 1b, d ) showed a major band with an apparent molecular weight of 80,000 and some minor proteins with higher apparent molecular weight. Advate showed trace bands at an apparent molecular weight of 250 and larger, which are compatible with vWf, while such bands were not seen for KO-GENATE Bayer or ReFacto. None of the recombinant proteins showed proteins or polypeptides with a molecular range between 70,000 and 10,000 ( fig. 1d ), while the plasma-derived Fanhdi, the albumin spot was so prominent that the intensity of other protein spots in these preparations was low by comparison. Apart from these, all plasma-derived preparations contained other plasma proteins as impurities. Due to the high specific activity of the recombinant proteins, the amounts of protein in the gels were very low resulting in faint spots.
Material and Methods

Factor
(pH 3-10) and an SDS-PAGE using a 7.5% polyacrylamide gel under reducing conditions to allow the FVIII-vWf complex to dissociate and the proteins to penetrate into the separating gel. Figure 2 shows the 2D protein maps for the FVIII and vWf concentrates. All plasma-derived clotting factor preparations (A, B, C, D, E, F, G, H) showed protein spots compatible with Z:\Karger\Karger_Zeitschriften_2010\2010_transfusionsmedizin_tmh\81000704_TMH_4_10\03_Texte\TMH_4_10_201001002_Kehrel_ZS.doc 14 The findings for HNP 1-3 and myeloperoxidase suggested that it would be appropriate to look for platelet activation markers. When activated, platelets secrete PF-4 and TSP-1, the major secretion protein from their a-granules. We therefore quantified the content of these two markers in the coagulation factor concentrates ( fig. 5 and 6 ).
All batches of Octanate contained PF-4 ( fig. 5 ). Up to 0.85 ng/IU of FVIII was detected. Traces of PF-4 were found in the batches of Faktor VIII SDH Intersero, Haemoctin SDH and Beriate P. No PF-4 was found in the recombinant FVIII products. TSP-1 was found in all tested batches of Immunate, Faktor VIII SDH Intersero, Haemoctin SDH, Wilate and Beriate P and in one tested batch of Haemate HS ( fig. 6 ). The amount of TSP-1 was below background level in Fanhdi. No TSP-1 was found in the recombinant FVIII products.
Complement Activation Markers
Complement fragment C3a was measured as a marker of complement activation ( fig. 7 ). There was distinct interbatch variability for C3a content, but all three batches of Faktor VIII SDH Intersero, Haemoctin SDH, Haemate HS and Octanate contained C3a. The C3a concentration in FVIII concentrates was up to 90 ng/IU FVIII. No C3a was found in Beriate P or in the recombinant FVIII products.
Discussion
FVIII is a plasma protein essential for the blood clotting process. The human FVIII protein is composed of a light and a heavy chain and has a molecular weight of 280,000 Da. Its domain organization is typically described as A1-A2-B-A3-C1-C2. ReFacto is a recombinant FVIII product in which the B-domain has been deleted to better stabilize the protein [6] . The single chain form of FVIII is readily proteolyzed in vivo and in vitro into multiple polypeptides with molecular weights ranging from 80,000 to 210,000 Da [7] . The main FVIII polypeptide band was found, as described by others [8] , at an apparent molecular mass of 80,000 Da.
Because of the huge difference in specific FVIII activity we had found between the recombinant FVIII products (4,000-14,000 IU/mg protein) and plasma-derived FVIII products (6-300 IU/mg protein), it was impossible to compare equal Cell Activation Markers 2D-PAGE is not sensitive enough to detect rare proteins, and many proteins are not resolved. We therefore used ELISA to quantify contaminants of cell activation markers and complement activation polypeptides. We measured the amount of HNP 1-3 ( fig. 3 ) and the enzyme myeloperoxidase ( fig. 4) in the coagulation factor concentrates because these peptides were secreted by neutrophils when activated.
All batches of Immunate STIM plus, Faktor VIII SHD and released from PMNL granules upon activation. HNP 1-3 are small cysteine-rich cationic proteins that belong to the first line of defense against bacteria, fungi and many enveloped and non-enveloped viruses [16] . They trigger the release of TNF-a and IFN-g from the macrophages, which act in an autocrine loop to enhance expression of CD32 and CD64 and thereby enhance phagocytosis [17] . Current evidence also suggests an important immunomodulative role of these peptides [18, 19] . It has been suggested that a-defensins are potential mediators of inflammatory cardiovascular diseases. They have also been shown to contribute to endothelial dysfunction, lipid metabolism disorders and the inhibition of fibrinolysis [19] . Nassar et al. [20] described a-defensins as risk factors for the presence and severity of arteriosclerosis, and as link between inflammation and arteriosclerosis. We have shown that human a-defensins can induce platelet activation [21] . An increased level of a-defensins was shown to be a blood marker for schizophrenia susceptibility [22] . These peptides have also been described as early markers for the development of colorectal adenomas and carcinomas, and it has been suggested that they might contribute to tumor growth [23] .
In the present study, we found up to 0.05 ng/IU of HNP 1-3 in plasma-derived FVIII concentrates. It is unknown whether this amount is clinically relevant in hemophilia patients, but it clearly shows that the plasma used for fractionation contained proteins released by activated neutrophils.
A further marker of neutrophil activation confirmed this result. Myeloperoxidase is a key inflammatory enzyme released by human neutrophils, which can generate highly reactive oxygen species that cause additional damage in cerebral or myocardial ischemia [24, 25] . An emerging and significant body of research that suggests that myeloperoxidase may be a critical mediator in dysfunctional lipoprotein formation and therefore also in atherogenic initiation and progression [26] [27] [28] .
We found up to 3.5 ng/IU myeloperoxidase in FVIII plasma concentrates. Interestingly, one product, Fanhdi, did not contain myeloperoxidase. This may be due to the purification procedure for this concentrate, which includes affinity chromatography on heparin. Because myeloperoxidase binds tightly to heparin [29] , it may be separated from FVIII. As for a-defensins, it is not kown whether the amount of myeloperoxidase in FVIII concentrates is clinically relevant, but myeloperoxidase is an active enzyme and there may be a cumulative effect over the time.
Activated leukocytes activate blood platelets and vice versa [30] . It is therefore not surprising that we found proteins from activated platelets in some FVIII concentrates, in addition to leukocyte activation markers.
The chemokine PF-4, also named CXCL-4, is a plateletspecific protein that is stored in platelet a-granules and released following platelet activation. PF-4 has been reported to be involved in monocyte arrest on inflamed endothelium [31] amounts of protein in the SDS gels. The total amount of protein in recombinant concentrates is very low. We therefore decided to separate 1 IU of the recombinant factor preparations in the 1D gels and 2 IU in the 2D gels. It is unknown whether the high amount of foreign proteins infused with plasma-derived FVIII concentrates is a burden for patients with hemophilia [9] .
In addition to FVIII proteins, the products we analyzed contained other proteins related to the purification and stabilization of FVIII. FVIII is an unstable protein, which is effectively stabilized in vivo by vWf. Most of the factor concentrates therefore contained vWf, either from co-purification, as in all plasma-derived products, or as traces of recombinant vWf co-expressed in Chinese hamster ovary (CHO) cells, as in Advate. We found no vWf in KOGENATE Bayer, Helixate NexGen or ReFacto.
Immunate, Fanhdi and Haemate HS are stabilized by human albumin, as seen in the distinct bands in the 1D SDS gel ( fig. 1a) . All plasma-derived products contained some fibrinogen. Preparations of plasma-derived clotting FVIII are complex protein mixtures as demonstrated by the great number of protein spots in the 2D-PAGE gels. Clifton et al. [10] recently compared three plasma-derived FVIII-vWf concentrates (Octanate, Haemoctin and Wilate) and detected inter-a-inhibitor proteins, fibrinogen and fibronectin in all three preparations as well as prothrombin in Octanate and Haemoctin.
The plasma used for FVIII concentrate preparations is derived from either source plasma or recovered plasma. Source plasma is collected in specialized plasma donation centers by plasmapheresis. Recovered plasma is collected from whole blood donations which are stored in blood bags for separation of cellular components for some hours. During the blood taking procedure, leukocyte depletion procedure or storage, the cellular components, the coagulation system or the complement system in the stored blood may be activated. Plasmapheresis techniques can also cause activation of platelets, complement and the coagulation process. The properties of the plasma are influenced by the time between blood donation and freezing of the plasma and whether the plasma is produced from whole blood or by plasmapheresis [11] .
Runkel et al. [12] found significantly greater levels of prothrombin fragments 1 and 2, PF-4 and neutrophil elastase in recovered plasma than in apheresis plasma. Even the material of the inline filters used for leukoreduction of the whole blood influences the properties of the plasma. Charged filters have been shown to cause substantial complement activation [13, 14] . The quality of the final coagulation factor concentrates is very closely linked to the quality of the starting plasma. This is why we looked for markers of cell activation and of complement activation in the final products.
Human neutrophils contain large amounts of the host defense a-defensin peptides HNP 1-3 [15] . They are secreted munological diseases such as insulin resistance [52] as well as to adaptive immune response [53] .
We observed high intra-product variability for C3a content. Up to 90 ng/IU of C3a was detected in two batches of Immunate and in all three batches of Faktor VIII SDH Intersero, Haemoctin, Haemate HS and Octanate, but none was found in Beriate P. C3a was found in buffy coat-derived platelet concentrates in clearly higher concentrations than in apheresis-derived platelet concentrates [54] . It is therefore likely that recovered plasma contains more C3a than apheresis plasma.
It is not known whether the activation markers that we had detected have a clinically relevant impact in hemophilia patients, but it has been shown in the past that the quality of the starting plasma used to produce the FVIII concentrate has a significant influence on its properties. Some batches of a plasma-derived, double-virus inactivated FVIII concentrate (marketed as Octavi SDPlus) that lead to a higher FVIII inhibitor formation were prepared from a starting plasma pools with elevated levels of coagulation markers [55] . Since activation of coagulation leads to activation of platelets and vice versa, it is likely that our batches of FVIII that contained cell activation markers were prepared from starting plasma with elevated levels of coagulation markers.
The concentrations of the impurities found in plasmaderived products were not high, but all substances found are pro-inflammatory. It is unknown whether the effect of these substances is additive and whether a lifelong contact with these activation products might have an influence on the health status of hemophilia patients. The rate of cardiovascular diseases in patients with hemophilia is lower than in agematched controls [56] , but this is probably due to the low concentration of FVIII and the consequent low coagulation capacity of the blood. Hemophilia patients treated with products that do not contain pro-inflammatory byproducts might have even have lower rates of cardiovascular diseases. Further research into this is therefore necessary.
